Human Microbiome and Diseases: Implications for Novel Therapies
A special issue of BioTech (ISSN 2673-6284).
Deadline for manuscript submissions: closed (15 March 2020) | Viewed by 199
Special Issue Information
Dear Colleagues,
The human microbiome has emerged as a new important player for human health status acquisition and maintenance. Recent advances in next generation sequencing technologies have increased our ability to study the complexity of microbial communities at deeper resolution. As a consequence, several studies have highlighted the presence of a microbial dysbiosis in an increasing number of diseases. Shedding light on the complex interactions between the human host and its microbial communities may provide novel insights into disease pathogenesis and their treatment. Indeed, this evidence is prompting metagenomic studies in the attempt to identify novel disease biomarkers for diagnosis and monitoring, and also novel actionable targets for the development of novel therapies based on microbiome manipulation. Dietary interventions and faecal microbiome transplantation, for example, have already shown their efficacy in clinical settings.
This Special Issue on the “Human microbiome and diseases” will focus on the state-of-the-art of this emerging field that highlights the important interplays between humans and microbes. The powerful understanding of these relationships still needs to overcome technological challenges specially to test the efficacy and safety of possible therapeutic approaches.
Manuscripts addressing these issues are welcome.
Dr. Valeria D’Argenio
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. BioTech is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- microbiome
- metagenomics
- novel biomarkers
- targeted therapies
- microbiome manipulation
- personalized medicine
- next generation sequencing
- microbes
- diet and microbiome
- faecal microbiome transplantation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
